Contract Services Clinical Research
Akeso’s Ivonescimab Plus Chemotherapy Granted Priority Review in China for First-Line Biliary Tract Cancer
Akeso, Inc. announced that ivonescimab in combination with chemotherapy for the first-line treatment of locally advanced or metastatic biliary tract cancer...
November 06, 2026 | News
Telix Joins Thera4Care to Advance FAP-Targeted Theranostics Research
Thera4Care is an initiative aimed at establishing an integrated theranostics ecosystem to broaden patient access in Europe Telix's fibroblast activation...
November 06, 2026 | News
NUHS, Singtel and Ericsson Expand Partnership to Advance AI-Enabled Healthcare and 6G Research
Extended collaboration will accelerate research and development in advanced connectivity and emerging 5G Advanced & future 6G tec...
November 05, 2026 | News
InventisBio’s Nomelcitinib Achieves Over 70% PASI 90 Response in Phase III Psoriasis Trial
InventisBio Co., Ltd. announced that its JH2 selective TYK2 inhibitor nomelcitinib (D-2570) has met both the primary endpoint and the key s...
November 04, 2026 | News
China's 2026 Reimbursement Lists: 10 Drugs That Will Show Where Beijing Is Paying, and the Commercial List's Second Year
Where things stand. As of 2 November 2026, the National Healthcare Security Administration (NHSA) has not published the 2026 National Reimbursement Drug Li...
November 03, 2026 | Regulatory
InventisBio’s Nomelcitinib Achieves Both Primary and Key Secondary Endpoints in Phase III Psoriasis Trial
InventisBio Co., Ltd. announced that its JH2 selective TYK2 inhibitor nomelcitinib (D-2570) has met both the primary endpoint and the key seconda...
November 03, 2026 | News
Lynk Pharmaceuticals Expands Simcere Partnership to Commercialise Zemprocitinib for Atopic Dermatitis in Greater China
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), announced that it has expanded its commercialization collaboration with Simcere Pharmaceutical Gro...
November 03, 2026 | News
Zhimeng Biopharma Completes Enrolment of 255 Patients in Pivotal ALS Phase II/III Trial in China
Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced that its independently developed next-generation potassium channel opener, CB03-154,...
November 03, 2026 | News
Pretzel Therapeutics Secures UK Approval to Advance PX578 into Phase II Trial for Rare Mitochondrial Disease
Regulatory milestone follows U.S. FDA clearance of Investigational New Drug application in August 2026 Initiation of Phase 2 Trial in POLG-PMD (POLG Dis...
November 02, 2026 | News
Immunome’s Varegacestat Moves into European Regulatory Review Following Positive Phase III Results
The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically significant improvements ac...
November 02, 2026 | News
Parse Biosciences and Nomic Bio Launch 100-Million-Cell Immune Dataset to Advance AI Drug Discovery
Parse Biosciences, a leading provider of scalable and publicly available single-cell sequencing technology, a subsidiary of QIAGEN, andNomic Bio, a leader ...
November 02, 2026 | News
Lynk Pharma’s Zemprocitinib Sustains Strong Rheumatoid Arthritis Responses Through 76 Weeks in Phase III Trial
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases,&...
October 30, 2026 | News
Ono Pharma’s ONO-1110 Shows Promising Pain Relief Signals Across Three Phase II Studies
Efficacy signals suggesting improvements in pain scores were observed in Phase 2 clinical studies in postherpetic neuralgia (PHN), fibromyalgia (FM), a...
October 30, 2026 | News
Lynk Pharmaceuticals Reports Sustained Phase III Efficacy of Zemprocitinib in Rheumatoid Arthritis Through Week 76
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...
October 29, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
